1/15
07:00 am
axsm
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
Low
Report
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
1/14
08:42 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/13
10:58 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $209.00 price target on by analysts at Robert W. Baird.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $209.00 price target on by analysts at Robert W. Baird.
1/13
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/12
04:54 pm
axsm
MoneyShow's Best Investment Ideas For 2026: Part 2 [Seeking Alpha]
Low
Report
MoneyShow's Best Investment Ideas For 2026: Part 2 [Seeking Alpha]
1/12
07:00 am
axsm
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Low
Report
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
1/8
08:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.
1/8
08:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.
1/6
09:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/5
08:42 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/5
07:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/5
03:24 am
axsm
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next [Yahoo! Finance]
Medium
Report
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next [Yahoo! Finance]
1/4
07:27 pm
axsm
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 [Yahoo! Finance]
Medium
Report
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 [Yahoo! Finance]
1/2
10:22 am
axsm
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? [Yahoo! Finance]
Low
Report
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? [Yahoo! Finance]
1/2
10:11 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/31
03:07 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/31
03:06 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $217.00 price target on by analysts at Mizuho.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $217.00 price target on by analysts at Mizuho.
12/31
02:14 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/31
12:41 pm
axsm
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 [Yahoo! Finance]
Low
Report
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 [Yahoo! Finance]
12/31
12:13 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/31
11:30 am
axsm
Axsome's Application for Alzheimer's Side Effect Treatment Gets FDA Priority Review; Shares Soar [Yahoo! Finance]
Medium
Report
Axsome's Application for Alzheimer's Side Effect Treatment Gets FDA Priority Review; Shares Soar [Yahoo! Finance]
12/31
09:22 am
axsm
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission [Yahoo! Finance]
High
Report
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission [Yahoo! Finance]
12/31
08:57 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Needham & Company LLC from $154.00 to $169.00. They now have a "buy" rating on the stock.
High
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Needham & Company LLC from $154.00 to $169.00. They now have a "buy" rating on the stock.
12/31
07:12 am
axsm
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation [Yahoo! Finance]
High
Report
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation [Yahoo! Finance]
12/31
07:00 am
axsm
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
High
Report
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation